RS64299B1 - Isporuka adeno asociranog virusnog vektora mikrodistrofina specifičnog za mišiće za lečenje mišićne distrofije - Google Patents

Isporuka adeno asociranog virusnog vektora mikrodistrofina specifičnog za mišiće za lečenje mišićne distrofije

Info

Publication number: RS64299B1
Authority: RS; Serbia
Prior art keywords: dystrophin; adeno; associated virus; muscular dystrophy; virus vector
Prior art date: 2017-03-17

Application number

RS20230434A

Other languages

English (en)

Inventor

Louise Rodino-Klapac

Jerry R Mendell

Original Assignee

Res Inst Nationwide Childrens Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-03-17

Filing date

2018-03-16

Publication date

2023-07-31

2018-03-16 Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital

2023-07-31 Publication of RS64299B1 publication Critical patent/RS64299B1/sr

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Microbiology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Marine Sciences & Fisheries (AREA)
Nutrition Science (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RS20230434A 2017-03-17 2018-03-16 Isporuka adeno asociranog virusnog vektora mikrodistrofina specifičnog za mišiće za lečenje mišićne distrofije RS64299B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762473148P	2017-03-17	2017-03-17
PCT/US2018/022881 WO2018170408A1 (en)	2017-03-17	2018-03-16	Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
EP18768395.8A EP3596222B1 (en)	2017-03-17	2018-03-16	Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy

Publications (1)

Publication Number	Publication Date
RS64299B1 true RS64299B1 (sr)	2023-07-31

Family

ID=63523321

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20230434A RS64299B1 (sr)	2017-03-17	2018-03-16	Isporuka adeno asociranog virusnog vektora mikrodistrofina specifičnog za mišiće za lečenje mišićne distrofije

Country Status (30)

Country	Link
US (2)	US20200199621A1 (sr)
EP (2)	EP3596222B1 (sr)
JP (2)	JP2020513811A (sr)
KR (2)	KR102683682B1 (sr)
CN (2)	CN118497275A (sr)
AR (1)	AR111292A1 (sr)
AU (1)	AU2018233732B2 (sr)
BR (1)	BR112019019248A2 (sr)
CA (1)	CA3056638A1 (sr)
CO (1)	CO2019011250A2 (sr)
CY (1)	CY1126080T1 (sr)
DK (1)	DK3596222T5 (sr)
EA (1)	EA201992201A1 (sr)
ES (1)	ES2948233T3 (sr)
FI (1)	FI3596222T3 (sr)
HR (1)	HRP20230522T1 (sr)
HU (1)	HUE062476T2 (sr)
IL (2)	IL311713A (sr)
LT (1)	LT3596222T (sr)
MA (1)	MA52112B1 (sr)
MD (1)	MD3596222T2 (sr)
MX (1)	MX2019011046A (sr)
PL (1)	PL3596222T3 (sr)
PT (1)	PT3596222T (sr)
RS (1)	RS64299B1 (sr)
SG (1)	SG11201908575SA (sr)
SI (1)	SI3596222T1 (sr)
TW (1)	TW201840850A (sr)
WO (1)	WO2018170408A1 (sr)
ZA (1)	ZA201906251B (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20200083495A (ko)	2017-10-20	2020-07-08	더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈	Nt-3 유전자 치료를 위한 방법 및 물질
EP3897689A1 (en) *	2018-12-21	2021-10-27	Northwestern University	Use of annexins in preventing and treating muscle membrane injury
CN113710809A (zh) *	2019-02-02	2021-11-26	联邦高等教育系统-匹兹堡大学	通过基因置换和抗炎的针对杜氏肌营养不良的一步基因疗法
CA3142194A1 (en) *	2019-05-30	2020-12-03	Solid Biosciences Inc.	Recombinant herpesvirales vector
WO2021042004A1 (en) *	2019-08-29	2021-03-04	Siemens Healthcare Diagnostics Inc.	Reagents and methods for detecting aav shedding
WO2021108755A2 (en) *	2019-11-28	2021-06-03	Regenxbio Inc.	Microdystrophin gene therapy constructs and uses thereof
EP4117783A4 (en) *	2019-12-16	2024-08-21	Res Inst Nationwide Childrens Hospital	COMPOSITIONS AND METHODS FOR RESTORING AND MAINTAINING DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX (DAPC)
AU2021265103A1 (en)	2020-04-29	2023-01-19	Bristol-Myers Squibb Company	Miniaturized dystrophins having spectrin fusion domains and uses thereof
WO2022029543A1 (en) *	2020-08-06	2022-02-10	Intas Pharmaceuticals Ltd.	Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy
CN116783293A (zh) *	2020-11-12	2023-09-19	精密生物科学公司	对肌营养不良蛋白基因中的识别序列具有特异性的工程化大范围核酸酶
EP4086276A1 (en)	2021-05-03	2022-11-09	Université d'Aix-Marseille	Composition for treating dysferlinopathy
EP4108263A3 (en) *	2021-06-02	2023-03-22	Research Institute at Nationwide Children's Hospital	Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
AU2022325165A1 (en) *	2021-08-05	2024-01-18	Insmed Incorporated	Adeno-associated virus particles and methods of use thereof
WO2023019168A1 (en) *	2021-08-11	2023-02-16	Ultragenyx Pharmaceutical Inc.	Compositions and methods for treating a muscular dystrophy
CN114316070B (zh) *	2021-12-29	2022-11-15	上海勉亦生物科技有限公司	用于治疗肌营养不良症的转基因表达盒
EP4215614A1 (en)	2022-01-24	2023-07-26	Dynacure	Combination therapy for dystrophin-related diseases
WO2023202469A1 (zh) *	2022-04-19	2023-10-26	康霖生物科技（杭州）有限公司	一种用于遗传性凝血因子缺乏病治疗的核酸构建体及其用途
WO2023248251A1 (en) *	2022-06-24	2023-12-28	Indian Institute Of Technology Kanpur	An optimized aav vector for gene therapy of muscular dystrophy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
ATE260980T1 (de)	1993-11-09	2004-03-15	Targeted Genetics Corp	Die erzielung hoher titer des rekombinanten aav- vektors
CA2176215C (en)	1993-11-09	2007-06-26	James P. Trempe	Stable cell lines capable of expressing the adeno-associated virus replication gene
US5658785A (en)	1994-06-06	1997-08-19	Children's Hospital, Inc.	Adeno-associated virus materials and methods
US5856152A (en)	1994-10-28	1999-01-05	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV vector and methods of use therefor
AU707866B2 (en)	1994-12-06	1999-07-22	Targeted Genetics Corporation	Packaging cell lines for generation of high titers of recombinant AAV vectors
FR2737730B1 (fr)	1995-08-10	1997-09-05	Pasteur Merieux Serums Vacc	Procede de purification de virus par chromatographie
US6143548A (en)	1995-08-30	2000-11-07	Genzyme Corporation	Chromatographic purification of adeno-associated virus (AAV)
EP1983057A3 (en)	1995-09-08	2009-01-07	Genzyme Corporation	Improved AAV vectors for gene therapy
US5910434A (en)	1995-12-15	1999-06-08	Systemix, Inc.	Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
CN1233291A (zh)	1996-09-06	1999-10-27	宾西法尼亚大学托管会	重组腺伴随病毒定向基因治疗的方法
US6566118B1 (en)	1997-09-05	2003-05-20	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2995542A1 (en)	1997-09-05	1999-03-11	Genzyme Corporation	Methods for generating high titer helper-free preparations of recombinant aav vectors
US6258595B1 (en)	1999-03-18	2001-07-10	The Trustees Of The University Of Pennsylvania	Compositions and methods for helper-free production of recombinant adeno-associated viruses
US7056502B2 (en)	2000-04-28	2006-06-06	The Trustees Of The University Of Pennsylvania	Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
WO2002053703A2 (en)	2001-01-05	2002-07-11	Children's Hospital, Inc.	Aav2 vectors and methods
DK2359869T3 (en)	2001-12-17	2019-04-15	Univ Pennsylvania	Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
US20080044393A1 (en) *	2004-07-16	2008-02-21	White Robert L	Retinal dystrophin transgene and methods of use thereof
JP5600064B2 (ja) *	2007-10-26	2014-10-01	アカデミシュジーケンハウスライデン	筋障害を相殺するための手段と方法
CN102459595A (zh) *	2009-04-24	2012-05-16	普罗森那技术公司	用于治疗dmd的包含肌苷的寡核苷酸
AU2012286994B2 (en)	2011-07-25	2017-08-10	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expression of DUX4
WO2013102904A1 (en) *	2012-01-05	2013-07-11	Hadasit Medical Research Services & Development Ltd.	Methods and compositions for gene delivery
CN104520428B (zh) *	2012-02-17	2018-09-21	费城儿童医院	将基因转移到细胞、器官和组织的aav载体组合物和方法
DE102012007232B4 (de)	2012-04-07	2014-03-13	Susanne Weller	Verfahren zur Herstellung von rotierenden elektrischen Maschinen
WO2014172669A1 (en) *	2013-04-20	2014-10-23	Research Institute At Nationwide Children's Hospital	Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs
JP2015092462A (ja)	2013-09-30	2015-05-14	Tdk株式会社	正極及びそれを用いたリチウムイオン二次電池
WO2015110449A1 (en) *	2014-01-21	2015-07-30	Vrije Universiteit Brussel	Muscle-specific nucleic acid regulatory elements and methods and use thereof
WO2015141521A1 (ja)	2014-03-21	2015-09-24	株式会社日立国際電気	基板処理装置、半導体装置の製造方法及び記録媒体
EP2960336A1 (en) *	2014-06-27	2015-12-30	Genethon	Efficient systemic treatment of dystrophic muscle pathologies
JP6197169B2 (ja)	2014-09-29	2017-09-20	東芝メモリ株式会社	半導体装置の製造方法
GB201507842D0 (en) *	2015-05-07	2015-06-17	New Royal Holloway & Bedford	Production of large-sized microdystrophins in an AAV-based vector configuration
MA45477A (fr) *	2016-04-15	2019-02-20	Res Inst Nationwide Childrens Hospital	Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire

2018
- 2018-03-16 RS RS20230434A patent/RS64299B1/sr unknown
- 2018-03-16 MA MA52112A patent/MA52112B1/fr unknown
- 2018-03-16 HU HUE18768395A patent/HUE062476T2/hu unknown
- 2018-03-16 EP EP18768395.8A patent/EP3596222B1/en active Active
- 2018-03-16 IL IL311713A patent/IL311713A/en unknown
- 2018-03-16 PL PL18768395.8T patent/PL3596222T3/pl unknown
- 2018-03-16 DK DK18768395.8T patent/DK3596222T5/da active
- 2018-03-16 CN CN202311798281.5A patent/CN118497275A/zh active Pending
- 2018-03-16 MD MDE20200102T patent/MD3596222T2/ro unknown
- 2018-03-16 BR BR112019019248A patent/BR112019019248A2/pt unknown
- 2018-03-16 SG SG11201908575S patent/SG11201908575SA/en unknown
- 2018-03-16 KR KR1020197029367A patent/KR102683682B1/ko active IP Right Grant
- 2018-03-16 WO PCT/US2018/022881 patent/WO2018170408A1/en active Application Filing
- 2018-03-16 CA CA3056638A patent/CA3056638A1/en active Pending
- 2018-03-16 MX MX2019011046A patent/MX2019011046A/es unknown
- 2018-03-16 IL IL269391A patent/IL269391B2/en unknown
- 2018-03-16 FI FIEP18768395.8T patent/FI3596222T3/fi active
- 2018-03-16 EP EP23167357.5A patent/EP4245852A3/en active Pending
- 2018-03-16 CN CN201880018893.9A patent/CN110997923B/zh active Active
- 2018-03-16 KR KR1020247022488A patent/KR20240112964A/ko active Search and Examination
- 2018-03-16 HR HRP20230522TT patent/HRP20230522T1/hr unknown
- 2018-03-16 JP JP2019550767A patent/JP2020513811A/ja active Pending
- 2018-03-16 EA EA201992201A patent/EA201992201A1/ru unknown
- 2018-03-16 US US16/494,614 patent/US20200199621A1/en not_active Abandoned
- 2018-03-16 PT PT187683958T patent/PT3596222T/pt unknown
- 2018-03-16 SI SI201830926T patent/SI3596222T1/sl unknown
- 2018-03-16 ES ES18768395T patent/ES2948233T3/es active Active
- 2018-03-16 LT LTEPPCT/US2018/022881T patent/LT3596222T/lt unknown
- 2018-03-16 AU AU2018233732A patent/AU2018233732B2/en active Active
- 2018-03-19 TW TW107109334A patent/TW201840850A/zh unknown
- 2018-03-19 AR ARP180100629A patent/AR111292A1/es unknown
2019
- 2019-09-20 ZA ZA2019/06251A patent/ZA201906251B/en unknown
- 2019-10-10 CO CONC2019/0011250A patent/CO2019011250A2/es unknown
2022
- 2022-06-03 US US17/832,325 patent/US20220364117A1/en active Pending
2023
- 2023-02-13 JP JP2023019888A patent/JP2023053254A/ja active Pending
- 2023-06-21 CY CY20231100291T patent/CY1126080T1/el unknown

Also Published As

Publication number	Publication date
JP2023053254A (ja)	2023-04-12
JP2020513811A (ja)	2020-05-21
EP4245852A3 (en)	2023-11-22
AU2018233732A1 (en)	2019-10-03
TW201840850A (zh)	2018-11-16
EP3596222A1 (en)	2020-01-22
CN118497275A (zh)	2024-08-16
IL269391B2 (en)	2024-09-01
MD3596222T2 (ro)	2023-08-31
SG11201908575SA (en)	2019-10-30
HRP20230522T1 (hr)	2023-08-04
CN110997923B (zh)	2024-01-02
DK3596222T3 (da)	2023-06-19
HUE062476T2 (hu)	2023-11-28
AU2018233732B2 (en)	2024-10-24
KR20240112964A (ko)	2024-07-19
MA52112A (fr)	2020-01-22
BR112019019248A2 (pt)	2020-04-28
MX2019011046A (es)	2019-10-17
EP4245852A2 (en)	2023-09-20
KR20190130591A (ko)	2019-11-22
CY1126080T1 (el)	2023-11-15
LT3596222T (lt)	2023-07-25
US20200199621A1 (en)	2020-06-25
EP3596222A4 (en)	2021-01-06
IL269391A (en)	2019-11-28
FI3596222T3 (fi)	2023-06-08
IL269391B1 (en)	2024-05-01
ES2948233T3 (es)	2023-09-06
PT3596222T (pt)	2023-06-20
EP3596222B1 (en)	2023-04-12
DK3596222T5 (da)	2024-09-02
IL311713A (en)	2024-05-01
EA201992201A1 (ru)	2020-03-19
US20220364117A1 (en)	2022-11-17
CO2019011250A2 (es)	2020-02-28
CN110997923A (zh)	2020-04-10
KR102683682B1 (ko)	2024-07-09
SI3596222T1 (sl)	2024-05-31
ZA201906251B (en)	2024-01-31
AR111292A1 (es)	2019-06-26
PL3596222T3 (pl)	2023-10-09
CA3056638A1 (en)	2018-09-20
WO2018170408A1 (en)	2018-09-20
MA52112B1 (fr)	2023-08-31

Publication	Publication Date	Title
IL269391A (en)	2019-11-28	Administration of muscle-specific microdystrophin using an adeno-associated virus vector for the treatment of muscular dystrophy
IL262194A (en)	2018-11-29	Administration of an adeno-associated virus vector of micro-dystrophin to treat muscular dystrophy
IL279521A (en)	2021-01-31	Adeno-associated virus vector for administration of muscle-specific microdystrophin for the treatment of muscular dystrophy
ZA201806863B (en)	2019-12-18	Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy
HK1247636A1 (zh)	2018-09-28	Rna指導的人類jc病毒和其他多瘤病毒的根除
IL259877A (en)	2018-07-31	Adeno-type viral vectors used to treat spinal muscular atrophy
EP3697915A4 (en)	2021-12-08	ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE SPECIFIC MICRODYSTROPHIN FOR THE TREATMENT OF MUSCLE DYSTROPHY
ZA201708039B (en)	2018-11-28	Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
HK1256903A1 (zh)	2019-10-04	治療人免疫缺陷病毒的治療組合物
MA47800A (fr)	2020-01-22	Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
IL259178A (en)	2018-06-28	Methods for treating muscular dystrophy
GB201720224D0 (en)	2018-01-17	Treatment of muscular dystrophies
HK1225969A1 (zh)	2017-09-22	利用低劑量的拉喹莫德治療克隆氏病
HUP1500226A2 (hu)	2016-12-28	Alapvetõen felfüggesztéses elven mûködõ állóképesség-fejlesztõ és izomerõsítõ funkcionális fitnesz eszköz